Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: viral infection vaccines - Protein Potential

Drug Profile

Research programme: viral infection vaccines - Protein Potential

Latest Information Update: 19 Jul 2016

At a glance

  • Originator Protein Potential
  • Class Dengue vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Dengue; Severe acute respiratory syndrome

Most Recent Events

  • 19 Jul 2016 Preclinical trials in Dengue (Prevention) in USA (Parenteral)
  • 19 Jul 2016 Preclinical trials in Severe acute respiratory syndrome (Prevention) in USA (Parenteral)

Development Overview

Introduction

Protein Potential is developing vaccines for the prevention of viral infections, including SARS (Severe Acute Respiratory Syndrome) and dengue fever. Development is at preclinical stage in the US.

Key Development Milestones

Protein Potential is developing vaccines for the prevention of SARS and dengue fever in preclinical studies in the US.

Drug Properties & Chemical Synopsis

  • Route of administration Parenteral
  • Formulation unspecified
  • Class Dengue vaccines, Viral vaccines
  • Mechanism of Action Immunostimulants
  • WHO ATC code

    J07B-X (Other viral vaccines)

  • EPhMRA code

    J7A9 (Other specified single component)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
Dengue - Prevention Preclinical USA Parenteral / unspecified Protein Potential 19 Jul 2016
Severe acute respiratory syndrome - Prevention Preclinical USA Parenteral / unspecified Protein Potential 19 Jul 2016

Commercial Information

Involved Organisations

Organisation Involvement Countries
Protein Potential Originator USA
Protein Potential Owner USA

Development History

Event Date Update Type Comment
19 Jul 2016 Phase Change - Preclinical Preclinical trials in Dengue (Prevention) in USA (Parenteral) Updated 19 Jul 2016
19 Jul 2016 Phase Change - Preclinical Preclinical trials in Severe acute respiratory syndrome (Prevention) in USA (Parenteral) Updated 19 Jul 2016
Back to top